Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06495229
PHASE3
Study of CM310 in Adolescent Subjects With Atopic Dermatis
Sponsor: Keymed Biosciences Co.Ltd
View on ClinicalTrials.gov
Summary
This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.
Official title: A Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of CM310 in Adolescent Patients With Atopic Dermatitis
Key Details
Gender
All
Age Range
12 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2024-08-02
Completion Date
2026-08-30
Last Updated
2025-10-02
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
CM310
Interleukin-4 receptor(IL-4Rα) monoclonal antibody
Locations (1)
Peking University People's hospital
Beijing, China